Verrica Pharmaceuticals Inc. (VRCA) News
Filter VRCA News Items
VRCA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VRCA News Highlights
- VRCA's 30 day story count now stands at 2.
- Over the past 9 days, the trend for VRCA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, SKIN and TOP are the most mentioned tickers in articles about VRCA.
Latest VRCA News From Around the Web
Below are the latest news stories about VERRICA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRCA as an investment opportunity.
Despite recent sales, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders remain the largest stockholders with 39% ownershipKey Insights Verrica Pharmaceuticals' significant insider ownership suggests inherent interests in company's expansion... |
Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?With Verrica Pharmaceuticals releasing positive Phase 3 trial results for a skin disease therapeutic, VRCA stock skyrocketed in response. |
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in JapanWEST CHESTER, Pa., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that its development and commercialization partner, Torii Pharmaceutical Co., Ltd. (“Torii”), reported positive top-line results from its Phase 3 trial of TO-208 (referred to as VP-102 and marketed as YCANTH™ in the U.S.) for the treatment of Mollu |
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call TranscriptVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript November 9, 2023 Verrica Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.54 EPS, expectations were $-0.22. Operator: Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being […] |
Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in LondonWEST CHESTER, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference, which is being held in London from November 14-16, 2023. Event details:Date: Wednesday, November 15, 2023Time: 2:00 pm GMTL |
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results– Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for |
Verrica Pharmaceuticals (NASDAQ:VRCA) investors are sitting on a loss of 72% if they invested five years agoLong term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see... |
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 9, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023. Individuals may participat |
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a virtual KOL event discussing the approval of YCANTH™ (cantharidin) topical solution for the treatment of molluscum contagiosum on Wednesday, October 11, 2023 at 11:00 AM ET. To register, click here. The event will feature Mark |
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment ConferenceWEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that that Ted White, Verrica President and CEO, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 5:00 pm ET. The Company will also be participating in one-on-one |